Analyst Ratings February 4, 2026

DA Davidson Lifts Almonty Industries Price Target to $18 as Tungsten Dynamics Shift

Analyst keeps Buy rating amid higher tungsten spot assumptions and Sangdong progress toward commercial output

By Sofia Navarro ALM
DA Davidson Lifts Almonty Industries Price Target to $18 as Tungsten Dynamics Shift
ALM

DA Davidson increased its price objective on Almonty Industries (ALM) to $18.00 from $12.00 and retained a Buy recommendation after updating commodity-price inputs and production assumptions. The broker cited sustained upward movements in tungsten spot prices, constrained mined output versus robust demand, and continued advancement of Almonty’s Sangdong project toward commercial production expected in late Q1 2026.

Key Points

  • DA Davidson raised Almonty Industries' price target to $18.00 from $12.00 and maintained a Buy rating.
  • Broker updated its model to reflect January’s average tungsten spot price from Fastmarkets and raised base price projections through 2028, citing constrained global mined output and strong demand.
  • Almonty’s shares trade at $13.09, up 51.99% year-to-date and up 805.25% over the past year; stock is trading near a 52-week high of $13.60.

DA Davidson raised its price target on Almonty Industries (NASDAQ:ALM) to $18.00 from $12.00 while keeping a Buy rating on the tungsten miner. The broker said the adjustment followed recent, sustained increases in tungsten spot prices and led it to revise pricing assumptions in its earnings model.

At the time of the report, Almonty’s shares were trading at $13.09. The stock has gained 51.99% year-to-date and has recorded a cumulative return of 805.25% over the past year. InvestingPro data noted the stock is trading near a 52-week high of $13.60.

DA Davidson said it updated its valuation model to incorporate January’s average spot price, as reported by Fastmarkets, and also raised its base price projections through 2028. The firm cited market conditions in which “global mined output supply remains constrained amid strong overall industry demand,” calling this an environment that favors tungsten producers such as Almonty.

Additionally, DA Davidson referenced Almonty’s Sangdong project, reporting that the development continues to move toward commercial production. The research note set an expectation for commercial production in the late first quarter of 2026. On the balance-sheet front, Almonty was noted to maintain a current ratio of 2.38, indicating that current assets exceed short-term obligations.

The research bulletin also pointed readers to further paid content, noting that InvestingPro provides eight additional ProTips and a comprehensive Pro Research Report covering Almonty Industries.


In separate corporate news included in the report, Almirall released third-quarter 2025 results showing earnings per share of $0.13, in line with analyst expectations. The company’s revenue came in at $260 million, marginally below the forecasted $260.8 million. Despite the revenue shortfall, Almirall’s shares saw a notable uptick in pre-market trading, the note said, with the earnings call emphasizing the company’s efforts to preserve a strong financial position. Investors are described as watching Almirall’s capacity to meet market expectations in upcoming quarters.

These developments leave Almonty in a market context shaped by higher tungsten spot prices, a constrained global mined supply, and the forward timeline for Sangdong’s commercial output. DA Davidson’s model changes and the retained Buy rating reflect the firm’s assessment of those factors within its near- and medium-term forecasts.

Risks

  • Timing and delivery risk for the Sangdong project, which is expected to reach commercial production in late first quarter of 2026 - impacts mining and materials sectors.
  • Dependence on tungsten spot price assumptions; future price movements could affect valuation and earnings projections - impacts commodities and industrial markets.
  • Almirall’s slight revenue miss versus forecasts highlights near-term execution and revenue risks for companies reporting into investor expectations - impacts pharmaceutical and healthcare sectors.

More from Analyst Ratings

UBS trims TransDigm price target slightly to $1,800, keeps Buy as aftermarket growth cools Feb 4, 2026 UBS Holds Neutral on Electronic Arts as Battlefield 6 Boosts Quarterly Results Feb 4, 2026 UBS Raises DaVita Target to $190, Cites Elevated 2026 EPS Outlook Feb 4, 2026 UBS Boosts FedEx Price Target to $412, Cites Pricing Levers and Cost Cuts Feb 4, 2026 DA Davidson Reaffirms Buy on Progress Software, Sees Large Upside to $70 Target Feb 4, 2026